Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis

Journal of Pineal Research

Volumn 52, Issue 3, 2012, Pages 322-331

  Zha, Lixia ^a   Fan, Lulu ^a   Sun, Guoping ^a   Wang, Hua ^a   Ma, Tai ^a   Zhong, Fei ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; cyclooxygenase 2; endoplasmic reticulum stress; hepatocellular carcinoma; melatonin

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MELATONIN; PROTEIN BAX; PROTEIN BCL 2; TUNICAMYCIN;

APOPTOSIS; ARTICLE; ENDOPLASMIC RETICULUM STRESS; HEPATOMA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SENSITIZATION;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLOOXYGENASE 2; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MELATONIN;

EID: 84862830150     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00946.x     Document Type: Article

References (54)

1. Kim I, Xu W, Reed JC,. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7: 1013-1030.
2. Ron D, Walter P,. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-529. (Pubitemid 46985379)
3. Malhotra JD, Kaufman RJ,. The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol 2007; 18: 716-731. (Pubitemid 350138453)
4. Xu C, Bailly-Maitre B, Reed JC,. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115: 2656-2664. (Pubitemid 41434389)
5. Kaufman RJ,. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002; 110: 1389-1398. (Pubitemid 35396907)
6. Ma Y, Hendershot LM,. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4: 966-977. (Pubitemid 39626220)
7. Dai R, Chen R, Li H,. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol 2009; 34: 1749-1757.
8. Hersey P, Zhang XD,. Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res 2008; 21: 358-367. (Pubitemid 351678087)
9. Stehle JH, Saade A, Rawshdeh O, et al., A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51: 17-43.
10. Reiter RJ,. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-180.
11. Reiter RJ,. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49: 654-664. (Pubitemid 23256791)
12. Arendt J,. Melatonin, circadian rhythms, and sleep. N Engl J Med 2000; 343: 1114-1116.
13. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ,. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010; 17: 4462-4481.
14. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N,. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49: 60-68.
15. Um HJ, Park JW, Kwon TK,. Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOP-mediated up-regulation of PUMA. J Pineal Res 2011; 50: 359-366.
16. Bejarano I, Redondo PC, Espion J, et al., Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells. J Pineal Res 2009; 46: 392-400.
17. Leja-Szpak A, Jaworek J, Pierzchalski P, Reiter RJ,. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-255.
18. Jung-Hynes B, Reiter RJ, Ahmad N,. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48: 9-19.
19. Okuda K,. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237. (Pubitemid 30123637)
20. Parkin DM, Bray F, Ferlay J, Pisani P,. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156. (Pubitemid 32911406)
21. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC,. Increase in primary liver cancer in the UK, 1979-1994. Lancet 1997; 350: 1142-1143. (Pubitemid 27454010)
22. Deuffic S, Poynard T, Buffat L, Valleron AJ,. Trends in primary liver cancer. Lancet 1998; 351: 214-215.
23. El-Serag HB, Mason AC,. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750. (Pubitemid 29114292)
24. El-Serag HB, Davila JA, Petersern NJ, Mcglynn KA,. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-823.
25. Avila MA, Berasain C, Sangro B, Prieto J,. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866-3884. (Pubitemid 43980482)
26. Ziedan NI, Kadri H, Westwekll AD,. The development of pro-apoptotic cancer therapeutics. Mini Rev Med Chem 2008; 8: 711-718.
27. Zhang LJ, Chen S, Wu P, et al., Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. Cancer Lett 2009; 274: 40-46.
28. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS,. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007; 67: 9809-9816. (Pubitemid 47621228)
29. Jiang CC, Mao ZG, Avery-Kiejda KA, Wade M, Hersey P, Zhang XD,. Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis 2009; 30: 197-204.
30. Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR,. Characterization of bortezomib-adapted I-45 mesothelioma cells. Mol Cancer 2010; 9: 110.
31. Jiang CC, Yang F, Throne RF, Zhu BK, Hersey P, Zhang XD,. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 2009; 11: 436-447.
32. Williams CS, Mann M, Dubois RN,. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916. (Pubitemid 30066236)
33. Kanaoka S, Takai T, Yoshida K,. Cyclooxygenase-2 and tumor biology. Adv Clin Chem 2007; 43: 59-78. (Pubitemid 44960960)
34. Hung JH, Su IJ, Lei HY, et al., Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 2004; 279: 46384-46392.
35. Hinz B, Brune K,. Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 2002; 300: 367-375.
36. Ulrich CM, Bigler J, Potter JD,. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140. (Pubitemid 43361545)
37. Rios ER, Venancio ET, Rocha NF, et al., Melatonin: pharmacological aspects and clinical trends. Int J Neurosci 2010; 120: 583-590.
38. Motilva V, Garcia-Maurino S, Talero E, Lllanes M,. New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res 2011; 51: 44-60.
39. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
40. Blask DE, Hill SM, Dauchy RT, et al., Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res 2011; 51: 259-269.
41. Blask DE, Brainard GC, Dauchy RT, et al., Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65: 11174-11184. (Pubitemid 41713389)
42. Blaks DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC,. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat 2003; 79: 313-320. (Pubitemid 36750938)
43. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L,. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 2009; 8: 337-346.
44. Hill SM, Blask DE,. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48: 6121-6126. (Pubitemid 18266811)
45. Cho SY, Lee HJ, Jeong SJ, et al., Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells. J Pineal Res 2011; 51: 87-93.
46. Proietti S, Cucina A, D'anselmi F, et al., Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 2011; 50: 150-158.
47. Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestie T,. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-24. (Pubitemid 30093182)
48. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA,. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006; 1757: 573-589. (Pubitemid 43993848)
49. Garcia-Navarro A, Gonzales-Puga C, Escames G, et al., Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205. (Pubitemid 47078925)
50. Mills E, Wu P, Seely D, Guyatt G,. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005; 39: 360-366.
51. Gupta M, Aneja S, Kohli K,. Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsy Behav 2004; 5: 316-321. (Pubitemid 38950090)
52. Arangino S, Cagnacci A, Angiolucci M, et al., Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 1999; 83: 1417-1419. (Pubitemid 29205758)
53. Cavallo A, Daniels SR, Dolan LM, Bean JA, Khoury JC,. Blood pressure-lowering effect of melatonin in type 1 diabetes. J Pineal Res 2004; 36: 262-266. (Pubitemid 38530474)
54. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, Reiter RJ,. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-2095.